ZDHHC7

Across TCGA pan-cancer cohorts, ZDHHC7 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZDHHC7 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher ZDHHC7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZDHHC7 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, SKCM, and PRAD are the cancer types where ZDHHC7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	II,III,IV	0.144	0.705	.004	30	view →
SKCM	DFS	Median	III,IV	0.169	0.617	.003	26	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.295	0.707	.005	6	view →
UCEC	DFS	Median	All	0.931	0.626	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZDHHC7–CESC (DFS)

Open the CESC breakdown →